119 related articles for article (PubMed ID: 37558565)
1. Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals.
Elshami M; Hoehn RS; Ammori JB; Hardacre JM; Selfridge JE; Bajor D; Mohamed A; Chakrabarti S; Mahipal A; Winter JM; Ocuin LM
HPB (Oxford); 2023 Dec; 25(12):1502-1512. PubMed ID: 37558565
[TBL] [Abstract][Full Text] [Related]
2. Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving versus Non-Minority-Serving Hospitals.
Lima HA; Alaimo L; Moazzam Z; Endo Y; Woldesenbet S; Katayama E; Munir MM; Shaikh C; Ruff SM; Dillhoff M; Beane J; Cloyd J; Ejaz A; Resende V; Pawlik TM
Ann Surg Oncol; 2023 Jul; 30(7):4363-4372. PubMed ID: 36800128
[TBL] [Abstract][Full Text] [Related]
3. Disparities in NCCN Guideline Compliant Care for Resectable Cholangiocarcinoma at Minority-Serving Versus Non-Minority-Serving Hospitals.
Tsilimigras DI; Dalmacy D; Hyer JM; Diaz A; Abbas A; Pawlik TM
Ann Surg Oncol; 2021 Dec; 28(13):8162-8171. PubMed ID: 34036428
[TBL] [Abstract][Full Text] [Related]
4. Disparities in Surgical Treatment of Resectable Pancreatic Adenocarcinoma at Minority Serving Hospitals.
Olecki EJ; Perez Holguin RA; Mayhew MM; Wong WG; Vining CC; Peng JS; Shen C; Dixon MEB
J Surg Res; 2024 Feb; 294():160-168. PubMed ID: 37897875
[TBL] [Abstract][Full Text] [Related]
5. ASO Author Reflections: Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving Versus Non-minority-Serving Hospitals.
Lima HA; Moazzam Z; Pawlik TM
Ann Surg Oncol; 2023 Jul; 30(7):4373-4374. PubMed ID: 36808592
[No Abstract] [Full Text] [Related]
6. Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally.
Lutfi W; Zenati MS; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Jul; 25(7):1860-1867. PubMed ID: 29691733
[TBL] [Abstract][Full Text] [Related]
7. Association of Care at Minority-Serving vs Non-Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States.
Cole AP; Nguyen DD; Meirkhanov A; Golshan M; Melnitchouk N; Lipsitz SR; Kilbridge KL; Kibel AS; Cooper Z; Weissman J; Trinh QD
JAMA Netw Open; 2019 Feb; 2(2):e187633. PubMed ID: 30707230
[TBL] [Abstract][Full Text] [Related]
8. Racial Disparities in Treatment for Rectal Cancer at Minority-Serving Hospitals.
Lu PW; Scully RE; Fields AC; Welten VM; Lipsitz SR; Trinh QD; Haider A; Weissman JS; Freund KM; Melnitchouk N
J Gastrointest Surg; 2021 Jul; 25(7):1847-1856. PubMed ID: 32725520
[TBL] [Abstract][Full Text] [Related]
9. Disparities in early-stage lung cancer outcomes at minority-serving hospitals compared with nonminority serving hospitals.
Deboever N; Correa AM; Feldman H; Mathur U; Hofstetter WL; Mehran RJ; Rice DC; Roth JA; Sepesi B; Swisher SG; Walsh GL; Vaporciyan AA; Antonoff MB; Rajaram R
J Thorac Cardiovasc Surg; 2024 Jan; 167(1):329-337.e4. PubMed ID: 37116780
[TBL] [Abstract][Full Text] [Related]
10. Association of Minority-Serving Hospital Status with Post-Discharge Care Utilization and Expenditures in Gastrointestinal Cancer.
Lima HA; Woldesenbet S; Moazzam Z; Endo Y; Munir MM; Shaikh C; Rueda BO; Alaimo L; Resende V; Pawlik TM
Ann Surg Oncol; 2023 Nov; 30(12):7217-7225. PubMed ID: 37605082
[TBL] [Abstract][Full Text] [Related]
11. Disparities in clinical trial enrollment among patients with gastrointestinal cancer relative to minority-serving and safety-netting hospitals.
Khan MMM; Munir MM; Woldesenbet S; Khalil M; Endo Y; Katayama E; Altaf A; Dillhoff M; Obeng-Gyasi S; Pawlik TM
J Gastrointest Surg; 2024 Jun; 28(6):896-902. PubMed ID: 38555017
[TBL] [Abstract][Full Text] [Related]
12. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
[TBL] [Abstract][Full Text] [Related]
13. Disparities in Stage-Specific Guideline-Concordant Cancer-Directed Treatment for Patients with Pancreatic Adenocarcinoma.
Hamad A; DePuccio M; Reames BN; Dave A; Kurien N; Cloyd JM; Shen C; Pawlik TM; Tsung A; McAlearney AS; Ejaz A
J Gastrointest Surg; 2021 Nov; 25(11):2889-2901. PubMed ID: 33768427
[TBL] [Abstract][Full Text] [Related]
14. The effect of treatment at minority-serving hospitals on outcomes for bladder cancer.
Fletcher SA; Gild P; Cole AP; Vetterlein MW; Kibel AS; Choueiri TK; Sonpavde GP; Preston MA; Pucheril D; Menon M; Sun M; Lipsitz SR; Trinh QD
Urol Oncol; 2018 May; 36(5):238.e7-238.e17. PubMed ID: 29454591
[TBL] [Abstract][Full Text] [Related]
15. The Association of Guideline-Concordant Sentinel Lymph Node Biopsy for Melanoma at Minority-Serving Hospitals.
Greene AC; Wong WG; Perez Holguin RA; Patel A; Pameijer CR; Shen C
Ann Surg Oncol; 2023 Jun; 30(6):3634-3645. PubMed ID: 36935433
[TBL] [Abstract][Full Text] [Related]
16. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement.
Jolissaint JS; Reyngold M; Bassmann J; Seier KP; Gönen M; Varghese AM; Yu KH; Park W; O'Reilly EM; Balachandran VP; D'Angelica MI; Drebin JA; Kingham TP; Soares KC; Jarnagin WR; Crane CH; Wei AC
Ann Surg; 2021 Dec; 274(6):894-901. PubMed ID: 34269717
[TBL] [Abstract][Full Text] [Related]
17. Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged?
Bertens KA; Massman JD; Helton S; Garbus S; Mandelson MM; Lin B; Picozzi VJ; Biehl T; Alseidi AA; Rocha FG
J Surg Oncol; 2018 Jun; 117(8):1655-1663. PubMed ID: 29761510
[TBL] [Abstract][Full Text] [Related]
18. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
20. Bayesian Approach to Understand the Association Between Treatment Down-staging and Survival for Patients With Pancreatic Adenocarcinoma.
da Costa WL; Tran Cao HS; Gu X; Massarweh NN
Ann Surg; 2022 Mar; 275(3):415-421. PubMed ID: 35120060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
